7509 Background: The FLIPI is potentially useful in predicting clinical outcome and comparing treatment results among clinical studies in FL. We recently reported the results of I-131 tositumomab as frontline treatment in 76 pts with advanced-stage FL (NEJM 325:441, 2005). A single 1-week course resulted in a 95% and a 75% overall and complete response (CR) rate, respectively, and at a median f...

conclusions: this study provides detailed information and case samples of radiodine contamination artifacts and non-physiological, non-metastatic extra-thyroidal i-131 accumulation in whole-body i-131 imaging. introduction: radioactive iodine has been used for more than 50 years for the treatment of thyroid diseases. differentiated thyroid cancers have the ability to trap iodine. therefore, rad...

Tositumomab and iodine I 131 tositumomab (Bexaar) therapeutic regimen targets monoclonal antibodies against the CD20 antigen expressed in non-Hodgkin lymphoma. This article reviews the mechanism of action and clinical indications for this regimen.

Objective: Resistance of metastatic lymph nodes (LNs) to high dose I-131 therapy is associated with high morbidity in patients with differentiated thyroid cancer. We evaluated the role of F-18 FDG PET/CT in the prediction of resistance to high dose I-131 therapy in patients with papillary thyroid cancer. Methods: The subjects were 307 patients who underwent total or near total thyroidectomy fol...

Introduction:The maximum tolerable activity (MTA) of I-131 in radioiodine therapy is an established surrogate quantity to ensure that the therapeutic activity does not produce severe damages to the bone marrow and lung. The aim of this study was to estimate the MTAs for high-risk patients using I-124 pre-therapy dosimetry and to compare the results with published literature. <...

objective: resistance of metastatic lymph nodes (lns) to high dose i-131 therapy is associated with high morbidity in patients with differentiated thyroid cancer. we evaluated the role of f-18 fdg pet/ct in the prediction of resistance to high dose i-131 therapy in patients with papillary thyroid cancer. methods: the subjects were 307 patients who underwent total or near total thyroidectomy fol...

Good morning Senator Specter, Senator Harkin, and Members of the Subcommittee. I am Richard Klausner, Director of the National Cancer Institute (NCI), and today I am presenting to you, for the first time, the completed NCI report estimating thyroid doses of Iodine-131 (I-131) received by Americans as a result of atmospheric nuclear bomb tests conducted at the Nevada Test Site. This study was co...